MannKind Co. (NASDAQ:MNKD – Get Rating) – Equities research analysts at HC Wainwright raised their FY2023 earnings per share (EPS) estimates for MannKind in a research report issued to clients and investors on Thursday, May 11th. HC Wainwright analyst O. Livnat now forecasts that the biopharmaceutical company will earn ($0.08) per share for the year, […]
StockNews.com upgraded shares of MannKind (NASDAQ:MNKD – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Friday morning. Separately, HC Wainwright boosted their price objective on MannKind from $6.00 to $7.00 in a research note on Monday, February 27th. MannKind Stock Up 7.1 % NASDAQ MNKD […]
StockNews.com upgraded shares of MannKind (NASDAQ:MNKD – Get Rating) from a hold rating to a buy rating in a research report report published on Friday. Separately, HC Wainwright raised their target price on shares of MannKind from $6.00 to $7.00 in a research note on Monday, February 27th. MannKind Stock Down 0.2 % NASDAQ:MNKD opened […]
MannKind Co. (NASDAQ:MNKD – Get Rating) – Equities researchers at SVB Leerink raised their Q2 2023 earnings estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, May 10th. SVB Leerink analyst T. Smith now anticipates that the biopharmaceutical company will earn ($0.03) per share for the quarter, up […]
MannKind Co. (NASDAQ:MNKD – Get Rating) – Equities researchers at SVB Leerink boosted their FY2024 earnings estimates for shares of MannKind in a report issued on Wednesday, May 10th. SVB Leerink analyst T. Smith now forecasts that the biopharmaceutical company will earn $0.13 per share for the year, up from their prior forecast of $0.09. […]